Table 1.
Sample information and neutralization activity
| Sample ID | Patient status | Days PSO | Age (years) | Sex | NT50 |
|---|---|---|---|---|---|
| 32 | COVID-19 moderate/severe | 15 | 31 | F | 1,691 |
| 33 | COVID-19 moderate/severe | 15 | 56 | M | 2,536 |
| 34 | COVID-19 moderate/severe | 11 | 56 | M | 5,353 |
| 35 | COVID-19 moderate/severe | 8 | 76 | M | 1,701 |
| 53 | COVID-19 moderate/severe | 33 | 65 | F | 1,116 |
| 36 | COVID-19 mild | 27 | 47 | F | 237 |
| 37 | COVID-19 mild | 31 | 43 | F | 22 |
| 38 | COVID-19 mild | 29 | 65 | M | 248 |
| 39 | COVID-19 mild | 31 | 29 | M | 217 |
| 50 | COVID-19 mild | 31 | 48 | F | 251 |
| 56 | COVID-19 mild | 29 | 22 | M | 28 |
| 58 | COVID-19 mild | 31 | 31 | F | 104 |
| 64 | COVID-19 mild | 34 | 28 | F | 227 |
| 68 | COVID-19 mild | 34 | 30 | M | 205 |
| 70 | COVID-19 mild | 26 | 36 | F | 78 |
| 72 | COVID-19 mild | 28 | 65 | M | 400 |
| 74 | COVID-19 mild | 26 | 65 | F | 130 |
| 76 | COVID-19 mild | 48 | 52 | F | 208 |
| 82 | COVID-19 mild | 43 | 29 | M | 212 |
| 182 | endemic CoV+ | NA | 61 | M | <20 |
| 183 | endemic CoV+ | NA | NA | NA | <20 |
| 41 | healthy adult | NA | NA | NA | <20 |
| 42 | healthy adult | NA | NA | NA | <20 |
| 43 | healthy adult | NA | NA | NA | <20 |
| 44 | healthy adult | NA | NA | NA | 993 |
| 45 | healthy adult | NA | NA | NA | <20 |
Samples were deidentified. F, female; M, male; NA, not available; PSO, post-symptom onset; NT50, reciprocal dilution at which viral infection is inhibited by 50%.